Application of pharmaceutical composition in preparation of medicine for treating sepsis

A composition and sepsis technology, applied in the direction of drug combination, active ingredients of hydroxyl compounds, antipyretics, etc., can solve problems such as increased intestinal mucosal permeability

Inactive Publication Date: 2015-04-29
YANTAI YENEPHARMA BIOMEDICAL
View PDF2 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cytokines are now thought to increase iNOS leading

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pharmaceutical composition in preparation of medicine for treating sepsis
  • Application of pharmaceutical composition in preparation of medicine for treating sepsis
  • Application of pharmaceutical composition in preparation of medicine for treating sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Replicate mouse CLP sepsis (severe) model

[0033] Male BALB / c mice, weighing 25-30 g, were depilated from the abdomen the day before the experiment. Pentobarbital sodium 40 mg / kg was injected intraperitoneally, fixed after anesthesia, and disinfected with iodine; a 1.5 incision was made along the midline of the abdomen to find the cecum, the mesentery was carefully stripped, and the cecum was ligated at the root of the cecum to avoid ligation of the ileum and cecal mesenteric vessels. The cecum was punctured three times with a 16-gauge needle, and a small amount of intestinal content was squeezed out. Then the cecum was returned to the abdominal cavity, and the abdominal wall incision was sutured layer by layer. After the operation, penicillin eye ointment was applied to prevent infection, and the wound was bandaged with a band-aid. About 20 minutes after the operation was completed, the mice regained their mobility. Before the CLP operation, the mice were ...

Embodiment 2

[0034] Embodiment 2: Effect of a single administration of the composition (4:1) on the survival rate of CLP model mice

[0035] BALB / c mice, male, 64, were randomly divided into sham operation group, sepsis model group, Edaravone treatment group (single i.v., 6mg / kg) and composition (4:1) treatment group ( Single i.v., 7.5mg / kg).

[0036] Composition (4:1) means Edaravone 3mg / kg+natural borneol 0.75mg / kg.

[0037] Edaravone injection, specification 5mL: 10mg (contains edaravone 10mg), produced by Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.; composition (4:1) injection, specification 5mL: 12.5mg (contains Edaravone 10mg and natural borneol 2.5mg, dissolved in 8% 1,2,-propanediol aqueous solution). Both are diluted to the required concentration with normal saline before use. 30 minutes after CLP modeling, the tail vein was injected slowly (<5 minutes).

[0038] The above-mentioned 4 groups of animals were counted every 4 hours after the death of animals, and the result...

Embodiment 3

[0041] Embodiment 3: Replicate rat CLP sepsis model

[0042] Male SD rats, weighing 250-280g, were anesthetized by intraperitoneal injection of pentobarbital sodium 40mg / kg, fixed, depilated, disinfected, and covered with sterile drapes. Make a 1.5 cm incision along the midline of the abdomen, find the cecum, carefully peel off the mesentery, and ligate the cecum at the root of the cecum to avoid ligating the ileum and cecal mesenteric vessels. The cecum was punctured twice with a 16-gauge needle, and a small amount of intestinal content was squeezed out. Then the cecum was returned to the abdominal cavity, and the abdominal wall incision was sutured layer by layer, and the operation was completed. Immediately subcutaneously inject 10 mL of preheated normal saline into the animal for anti-shock. Before the CLP operation, the rats were lively and active, with smooth fur, rosy lips and front and rear paws, active eating and drinking, and normal defecation; after the CLP operat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a use of a pharmaceutical composition in the manufacture of medicament for treating related diseases caused by endotoxemia. The pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or pharmaceutically acceptable salt thereof and borneol. The diseases include, but are not limited to, systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, sepsis related disseminated intravascular coagulation, acute lung injury, acute respiratory distress syndrome, multiple organ failure syndrome, septic brain injury and inflammatory lung injury caused by other reasons, including but not limited to bacterial pneumonia.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the application of a composition of 3-methyl-1-phenyl-2-pyrazolin-5-one and borneol in treating related diseases caused by endotoxemia caused by various reasons. Background technique [0002] Sepsis is a common complication after severe trauma (burn) injury, shock, and major surgery, and can further develop into septic shock and multiple organ dysfunction syndrome (MODS). The incidence of sepsis is high, with more than 18 million cases of severe sepsis every year in the world, and 750,000 sepsis patients in the United States every year, and this number is still increasing at a rate of 1.5% to 8.0% per year. Sepsis is a dangerous condition with a high fatality rate. About 14,000 people worldwide die from its complications every day, and about 215,000 people die in the United States every year. According to foreign epidemiological surveys, the fatality rate of sepsis has surpassed that of myo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4152A61P31/00A61P29/00A61P11/00A61K31/045
CPCA61K31/045A61K31/4152A61K2300/00A61P11/00A61P29/00A61P31/00
Inventor 张正平杨士豹华垚陈荣王鹏龚兆龙
Owner YANTAI YENEPHARMA BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap